Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs
NEVE ILAN, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that HealthCCSng, an AI-powered solution created by Nanox’s deep-learning medical imaging analytics subsidiary, Nanox.AI, was used in a clinical study evaluating routine CT scans and found that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium (CAC), a proven indicator of future cardiac events. The study was sponsored by Nanox.AI and conducted by the Beilinson Hospital, one of the largest and most renowned multidisciplinary medical institutions in Israel, and utilized Nanox.AI’s HealthCCSng, an FDA-cleared and CE marked tool designed specifically for cardiac health assessment.
- Nanox.AI’s HealthCCSng solution utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC category.
- CAC is the strongest predictor of future cardiac events, with patients in the highest category being over 20 times more likely to suffer a cardiac event.
- “The patients in this study received routine CT scans that had nothing to do with a cardiac concern.
- HealthCCSng supports clinicians in diagnosing patients with cardiovascular disease who were previously undetected, while stratifying such patients so that they can obtain the appropriate preventative cardiac care and treatment.